COMMUNIQUÉS West-GlobeNewswire

First Choice Healthcare Solutions Announces Strategic Partnership and Equity Investment with Steward Health Care
08/02/2018
Management to Host Shareholder Update Conference Call to Discuss Strategic Partnership in Further Detail on Thursday, February 8th at 11:00 a.m. ET MELBOURNE, Fla., Feb. 07, 2018 (GLOBE NEWSWIRE) -- First Choice [...]
MediciNova Announces Pricing of Underwritten Public Offering of Common Stock
08/02/2018
LA JOLLA, Calif., Feb. 07, 2018 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV ) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875 [...]
Gemphire Announces Proposed Public Offering of Common Stock
07/02/2018
LIVONIA, Mich., Feb. 07, 2018 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ: GEMP ), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders [...]
Precision Optics Corporation Schedules Second Quarter Conference Call
07/02/2018
GARDNER, Mass., Feb. 07, 2018 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (OTCQB:PEYE) (the "Company") announced that it intends to release its financial results for the fiscal year 2018 second quarter ended [...]
Akari Therapeutics to Present at the Leerink Partners Global Healthcare Conference
07/02/2018
NEW YORK and LONDON, Feb. 07, 2018 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ: AKTX ) (“Akari” or “the Company”), a biopharmaceutical company focused on the development and commercialization of innovative [...]
Tonix Pharmaceuticals to Present at the 20th Annual BIO CEO & Investor Conference in New York City
07/02/2018
NEW YORK, Feb. 07, 2018 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP ) (Tonix), a clinical-stage biopharmaceutical company focused on discovering and developing pharmaceutical products to treat [...]
Insmed to Present at the Leerink Partners 7th Annual Global Healthcare Conference
07/02/2018
BRIDGEWATER, N.J., Feb. 07, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq: INSM ), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced that Will Lewis, [...]
Prothena to Participate in the Leerink Partners 7th Annual Global Healthcare Conference
07/02/2018
DUBLIN, Ireland, Feb. 07, 2018 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ: PRTA ), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel therapies in [...]
ConforMIS Reports Fourth Quarter and the Year Ended 2017 Financial Results; Reiterates 2018 Financial Guidance
07/02/2018
BILLERICA, Mass., Feb. 07, 2018 (GLOBE NEWSWIRE) -- ConforMIS, Inc. (NASDAQ: CFMS ), a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture and sell [...]
Intercept to Report 2017 Full Year Financial Results on February 14 and Present at Upcoming Conferences
07/02/2018
NEW YORK, Feb. 07, 2018 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT ), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non- [...]
GBT Announces Participation at the Leerink Partners 7th Annual Global Healthcare Conference
07/02/2018
SOUTH SAN FRANCISCO, Calif., Feb. 07, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT ) today announced that it will present at the Leerink Partners 7 th Annual Global Healthcare Conference [...]
Sunesis Pharmaceuticals Appoints Industry Veteran H. Ward Wolff to the Board of Directors
07/02/2018
SOUTH SAN FRANCISCO, Calif., Feb. 07, 2018 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS ) today announced that H. Ward Wolff has been appointed to the Sunesis Board of Directors. Mr. Wolff brings over [...]
Sonoma Pharmaceuticals Reports Record Total Revenue of $4.8 million for Third Quarter FY 2018 with Year over Year Product Revenue Growth of 46%
07/02/2018
Product revenue up 12% compared to September 2017 quarter U.S. product revenue up 27% compared to the September 2017 quarter Cash on hand equals $8.6 million at quarter end Conference Call Begins at 4:30pm EST Today [...]
pSivida Corp. Reports Second Quarter FY2018 Results; Continues to Achieve Milestones and Timelines
07/02/2018
Newly Released Second Phase 3 Study Data for Durasert Three-Year Treatment for Posterior Segment Uveitis Shows Positive Efficacy and Safety Profile Maintained at 12 Months Awaiting FDA Decision to Accept NDA Submission [...]
MediciNova Announces Proposed Underwritten Public Offering of Common Stock
07/02/2018
LA JOLLA, Calif., Feb. 07, 2018 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV ) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), [...]
Jeff Immelt Appointed Chairman of athenahealth Board of Directors
07/02/2018
WATERTOWN, Mass., Feb. 07, 2018 (GLOBE NEWSWIRE) -- athenahealth, Inc. (NASDAQ: ATHN ), a leading provider of network-enabled services for hospital and ambulatory clients nationwide, today announced that its Board of [...]
pSivida's Second Phase 3 Study for Durasert™ Three-year Treatment for Posterior Segment Uveitis Maintains Positive Efficacy and Safety Profile at 12 Months
07/02/2018
Highly Significant Difference Between Durasert and Sham in Prevention of Uveitis Recurrence at 12 Months Fiscal Q2 2018 Results Conference Call Scheduled for Today at 4:30 p.m.ET WATERTOWN, Mass., Feb. 07, 2018 (GLOBE [...]
Amicus Therapeutics Announces Additional Positive Data in Pompe Disease Phase 1/2 Study at 14th Annual WORLDSymposium™
07/02/2018
Consistent and Durable Responses Across Key Measures of Safety, Functional Outcomes and Biomarkers Out to Month 12 Very Low Rate (<1%) of Infusion Associated Reactions Maintained After 550+ Infusions CRANBURY, N.J. [...]
Adverum Biotechnologies Announces Proposed Public Offering of Common Stock
07/02/2018
MENLO PARK, Calif., Feb. 07, 2018 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM ), a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases, today [...]

Pages